Key Highlights

  • 10.88% is the intraday decline in Novavax (NASDAQ:NVAX) on October 16, 2026, to USD 11.43, per published market data. The implied prior close of USD 12.83 is own arithmetic, above the USD 12.56 close of October 5 and below the 52-week high of USD 13.04.
  • 20.08% was the Novavax (NASDAQ:NVAX) gain on October 5, 2026, to USD 12.56, its best day since January. Triggers were a Vaxcyte (NASDAQ:PCVX) late-stage pneumonia vaccine result and unconfirmed reports of a suspected plague case in Russia.
  • 27.92% of the float in Novavax (NASDAQ:NVAX) is sold short, with 8.1 days to cover, per published market data. FINRA data for the September 30, 2026 settlement show 46,046,946 shares short, down 3,828,264 from September 15.
  • USD 723.9 million was cash, equivalents, marketable securities and restricted cash at Novavax (NASDAQ:NVAX) on June 30, 2026, against long-term debt of USD 291.5 million and a stockholders' deficit of USD 190.7 million, per the August 6, 2026 results.

Rally, Reversal and Catalyst Review

The market is trading Novavax (NASDAQ:NVAX) as a lottery ticket on outbreak headlines, even though the company has no plague vaccine. The shares rose 20.08% on October 5, 2026 as short sellers covered, and fell 12% on October 6 when the World Health Organization said tested contacts showed no plague. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026 for today's 10.88% decline; it reads as a continuation of the unwinding.

Short Interest and Squeeze Arithmetic

Shorts held 46.05 million shares at the September 30, 2026 settlement, worth USD 526 million at USD 11.43 (own arithmetic). Days to cover of 8.1 means shorts need 8.1 sessions of volume to exit, so a rally forces covering and a fall lets shorts keep profit. Short interest had already fallen 7.7% over two weeks (own arithmetic), before the October 15 settlement figure due October 26, 2026. Think of a squeeze as a revolving door: covering pushes the price up, then exits as the news fades. Providers conflict, from 27.9% of shares outstanding to 30.43% of float.

Fundamentals and Dated Risks

Second quarter revenue was USD 56.7 million, down 76% from USD 239.2 million, because the year-earlier quarter held USD 202 million of milestone and amendment revenue. Net loss was USD 53.4 million. Guidance for adjusted 2026 revenue is USD 235 million to USD 275 million, so the USD 1.88 billion market value is 7.4 times the midpoint (own arithmetic). Sanofi (NASDAQ:SNY) owes a USD 125 million payment if it starts a Phase 3 combination trial, and USD 75 million at technology transfer completion, expected mid-2027 per the company. Third quarter results are expected in early November 2026, date unconfirmed.

Where Things Stand

The decline reflects a rally that rested on sector sentiment, not on Novavax (NASDAQ:NVAX) fundamentals, and no company-specific catalyst explains the 10.88% drop. The 20.08% gain on October 5, 2026 combined a rival vaccine success, plague headlines and short covering, and the WHO assessment removed the plague premium. Supporting the equity is USD 723.9 million of cash and USD 235 million to USD 275 million of guided revenue. Weighing on it are the 76% revenue decline, a stockholders' deficit, and 27.92% of float still short. The next dated catalysts are the October 26, 2026 FINRA release and the early November earnings report.